Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Authors
Oza, APignata, S
Poveda, A
McCormack, M
Clamp, Andrew R
Schwartz, B
Cheng, J
Li, X
Campbell, K
Dodion, P
Haluska, F
Affiliation
Princess Margaret Cancer Centre, Toronto, ON, CanadaIssue Date
2015-06-15
Metadata
Show full item recordAbstract
The prognosis for women with recurrent and metastatic endometrial cancer is poor, and improved therapies are needed. The mammalian target of rapamycin (mTOR) pathway is an important target, and mTOR inhibitors show clinical activity in endometrial cancer.Citation
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. 2015: J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2014.58.8871PubMed ID
26077241Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2014.58.8871